Mississauga company gets almost $200 mil from federal government to produce vaccines, create over 200 jobs

Mississauga | Ontario | Business |

By

Published May 18, 2021 at 6:24 pm

resiliance_bio_inc_exterior-3

A Mississauga-based company is getting a significant influx of cash from the federal government to produce made-in-Canada vaccines. 

National Resilience, Inc., a company building a biopharmaceutical manufacturing ecosystem, just announced that the Canadian government will invest $199.2 million in the company’s Mississauga-based subsidiary Resilience Biotechnologies Inc. (RBI) to “modernize and expand production capacity.”

“The Government of Canada’s top priority is to protect the health and safety of Canadians. Today’s contribution to Resilience Biotechnologies Inc. is another important step to support Canada’s leadership in the life sciences sector and to build future pandemic preparedness,” said François-Philippe Champagne, Minister of Innovation, Science and Industry, in a statement. 

“These investments are also creating well-paying jobs and helping to grow Canada’s life sciences ecosystem as an engine for our economic recovery.” 

RBI is a 136,000 sq. ft. biomanufacturing facility that currently provides process and analytical development, scale-up, drug substance and drug product / fill finish manufacturing for a variety of medicines.

The investment is being made through the government’s Strategic Innovation Fund. 

According to the company, the funding will help increase manufacturing capacity for vaccines and therapeutics, including novel technologies such as mRNA that are now being used to fight COVID-19. 

The investment will create 205 new full-time positions at the Mississauga facility.

“Resilience was founded during the pandemic to build a better system for manufacturing complex medicines to fight deadly diseases,” said Rahul Singhvi, Sc.D, Chief Executive Officer of Resilience, in a statement. 

“This partnership with the Government of Canada will help prepare Canada for future pandemics and strengthen the country’s biopharmaceutical ecosystem.”

insauga's Editorial Standards and Policies advertising